CARPL.ai vs Tempus AI
A detailed comparison to help you choose between CARPL.ai and Tempus AI.
🏆
Verdict: Tempus AI wins
Tempus AI scores 4.1/5, edging out CARPL.ai at 3.9/5. Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access.
CARPL.ai AI-powered radiology platform for seamless healthcare integration | Tempus AI AI for precision medicine and clinical genomics | |
|---|---|---|
| Rating | 3.9 (1 review) | 4.1 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $99/mo | From $1000/mo |
| Best For | Hospital radiology departments and imaging networks that want to evaluate, deploy and monitor AI from many vendors through one PACS integration instead of contracting each algorithm separately. | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | api accessteam featuresgdpr compliant | ssoteam features |
| Visit CARPL.ai → | Visit Tempus AI → |
CARPL.ai
Pros
- + Single integration point replaces per-vendor AI integrations; the PACS/RIS-agnostic gateway design is documented in the 510(k) summary, not just marketing
- + Validation-before-purchase workflow runs candidate algorithms on your own institutional data with AUC, bias and fairness reports before any contract
- + Universal AI Viewer handles a wider range of AI output formats than most single-vendor tools — DICOM SEG, GSPS, structured reports, ROI coordinates and secondary captures
- + Regulatory transparency is better than the category norm: each hosted algorithm shows its own FDA 510(k) number with a link to the decision letter
- + On-premise, private cloud or any major cloud deployment, with named PACS partners (Agfa, Intelerad, DeepHealth, Ramsoft, PaxeraHealth)
Cons
- - No public pricing, no self-serve trial and no free tier — every evaluation goes through an enterprise sales process
- - The FDA 510(k) clearance covers image management and viewing only; it carries no diagnostic performance claim and validates none of the hosted algorithms
- - Marketplace counts conflict across CARPL's own pages (110+ apps in May 2024, 175+ in June 2025, 275+ and 300+ on the current homepage)
- - Mammography use is restricted: no lossy-compressed or digitised film for primary interpretation, and compliant displays are required
- - Built for institutional IT — there is no path for an individual radiologist or small practice, and customers cannot add algorithms themselves
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Frequently Asked Questions
Which is better, CARPL.ai or Tempus AI?▼
Tempus AI scores higher at 4.1/5 vs 3.9/5 for CARPL.ai, making it the better-rated option in our comparison.
What is the difference between CARPL.ai and Tempus AI?▼
CARPL.ai: CARPL.ai is a vendor-neutral platform for radiology AI, letting hospitals test, deploy and monitor imaging algorithms through one interface. Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties.
Is CARPL.ai or Tempus AI more affordable?▼
CARPL.ai starts at €99/mo, Tempus AI starts at €1000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.